Genentech maintained at outperform by RBC

RBC Capital Markets analyst Jason Kantor kept Genentech, Inc. at outperform, average risk, after IMS revised the last two months of Avastin estimates downward, with other estimates under review. The second-quarter estimates were too high, leading to incorrectly forecasted second-quarter sales, according to the analyst. Shares of the South San Francisco, Calif.-based biotherapeutic company were down $1.17, or 1.40%, at $82.20. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.